Inogen (INGN) Q3 2026 Earnings Call Transcript

INGN's Q3 2026 print landed with a split: U.S. sales grew 3.8% on new products, while international sales fell 9% on European customer softness.

Management paired the mixed top line with two restructuring moves. Inogen sold its U.S. oxygen rental business for $24.8 million and announced a $20 million cost-reduction program aimed at accelerating profitability. Full-year guidance calls for revenue of $298-301 million and an adjusted net loss of $7-8 million.

New CEO Andrew Reding laid out a plan to streamline operations and expand into adjacent respiratory markets with the Aurora and Voxi products. Interpretation: the rental divestiture and cost program point to a company prioritizing margin repair over broad growth, while the adjacent-market push is the growth leg of the thesis and remains unproven in these numbers.

The geographic split is the key tension. A 3.8% U.S. gain tied to new products suggests product refresh is gaining traction at home, but a 9% international decline shows Europe is a drag that could cap the revenue range if softness persists.